Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...
While chimeric antigen receptor (CAR) T cell therapy is an essential therapeutic option for prolonging survival in patients with relapsed or refractory non-Hodgkin lymphomas (NHL), profound immune ...
B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy demonstrated safety in patients with multiple myeloma (MM) and central nervous system (CNS) involvement, achieving an ...
At ASH 2025, investigators reported early results from the first-in-human phase 1 inMMyCAR study evaluating KLN-1010, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback